ESTRO ACROP and SIOPE recommendations for myeloablative total body irradiation in children.

Guideline ID: 3236 Published: 2022 Aug

European Society for Radiotherapy and Oncology (ESTRO)

Hoeben BAW, Pazos M, Seravalli E, et al. ESTRO ACROP and SIOPE recommendations for myeloablative Total Body Irradiation in children. Radiother Oncol. 2022 Aug;173:119-133. [231 references] *PubMed*

View Original Guideline

Overview

Guideline Objective

To provide recommendations regarding myeloablative total body irradiation (TBI) techniques and toxicities in children

Patient Population

Children with high-risk acute lymphoblastic leukemia (ALL) or recurring hematologic malignancies

Recommendations

Recommendation Statements

Major interventions covered in this guideline include:

- Indications for TBI-based myeloablative conditioning for hematopoietic stem cell transplantation (HSCT)
- Pre-HCST patient evaluation and testing
- Considerations for dose rate, including fractionated TBI (fTBI) schedules and radiotherapy boost
- Guidance on conventional TBI at extended source to skin distance (SSD) setup and highly conformal optimized TBI at source-axis distance (SAD) setup

Note: Full recommendation statements have not been provided because this guideline does not meet EGT's systematic review of the evidence criteria. Refer to the original guideline for more information.

Evidence Rating Scheme

Refer to the original guideline documentation for more information.

Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

Related Content

Supporting Documents

- Supplement 1: Background Literature Review and Expansion.
- Supplement 2: Pulmonary Toxicity in (Pediatric) Patients Receiving HSCT with Fractionated TBI Table.
- Supplement 3: Chronic Renal Disease in (Pediatric) Patients Receiving HSCT with Fractionated TBI Table.

- Supplement 4: Eye/Lens Toxicity in (Pediatric) Patients Receiving HSCT with Fractionated TBI Table.
- Supplement 5: Liver Toxicity in (Pediatric) Patients Receiving HSCT with Fractionated TBI Table.
- Supplement 6: Cardiovascular Toxicity in (Pediatric) Patients Receiving HSCT with Fractionated TBI Table.
- Supplement 7: Endocrinopathies in (Pediatric) Patients Receiving HSCT with Fractionated TBI Table.

Implementation Tools

No implementation tools available.

Patient Education

No patient education materials available.

Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.

Copyright © 2025 ECRI